12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLPG0634: Phase IIa data

Top-line data from a double-blind, international Phase IIa trial in 91 patients with active RA who had an inadequate response to methotrexate showed that once-daily 300 mg oral GLPG0634 significantly improved ACR response rates, DAS28 and HAQ-DI scores, and CRP levels vs. placebo. Galapagos, which said the trial was not powered to detect statistical significance, declined to provide details. GLPG0634 was well tolerated with no serious adverse events reported. Patients received placebo or once-daily 30, 75, 150 or 300 mg GLPG0634 for 4 weeks. All patients...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >